• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Eye disease tracked to a glitch in starburst cells
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/From Our Labs

Eye disease tracked to a glitch in starburst cells

A cellular computing error wreaks havoc on vision.

By
K.E.D. Coan
May 09, 2016

You know those shaky smartphone videos? Imagine a disease that makes you see everything like that.  Congenital nystagmus causes involuntary eye movements that make it difficult to steadily view objects. In extreme cases, patients are rendered legally blind. Little is known about the debilitating condition, but a team of scientists recently uncovered major clues about its origins.  

Researchers previously suspected that a gene called FRMD7 was involved. After all, seventy percent of nystagmus patients have mutations in FRMD7, which also happens to be primarily expressed in the retina. But no one knew its precise role in nystagmus. 

Enter Botond Roska, a neurobiologist and principal investigator at the Novartis-affiliated Friedrich Miescher Institute for Biomedical Research. His group discovered that FRMD7 mutations wreak havoc by sabotaging exquisite retinal cells called starbursts (above). Specifically, the mutations interfere with the cells’ ability to decode sideways movement. This finding, published in Neuron, provides critical insight for understanding and potentially treating nystagmus.  

“Nystagmus is a very common disease—affecting 1 in 1,500 people—but it’s still poorly understood,” says Roska. “We’ve now shown that FRMD7 mutations keep starburst cells from doing their jobs.” 

Although there was a clear correlation between mutated FRMD7 and nystagmus, Roska’s group first needed to confirm that the mutation did, in fact, cause nystagmus-like symptoms. To do this, they created genetically-modified mice that lacked functional FRMD7. Surprisingly, these mice didn’t display involuntary eye movements. They had, however, lost the reflex to track horizontal movement, another defining symptom of nystagmus.

Next, Roska’s group identified exactly which cells were affected by the mutation by profiling FRMD7 gene expression in the retina. Across all cell types, they found that only one was expressing FRMD7: starburst cells. 

It’s easy to see how the starburst cell got its name. Many arms radiate from a central body. And these projections play a critical function, connecting with other cells in a neural circuit that processes vision. Starburst cells are known to be essential for deciphering and transmitting information about movement in all directions. Given this role, it wasn’t surprising for starburst cells to be implicated in nystagmus. But, there was something peculiar about the starburst cells in the genetically-modified mice. 

“The starburst cells looked perfectly healthy,” says Roska. “There was no degeneration or failure to connect with neighboring neurons or any other indication that there was something wrong.”  

The researchers had to look at the electrical signals between starbursts and their neighboring motion-detector cells to pinpoint the problem: starbursts could no longer tell left and right motion-detector cells apart. This meant that the mice lacked the reflex to track motion and the ability to distinguish whether an object moved left or right.   

“Starburst cells are a hub for all types of motion-detecting cells, and they learn to distinguish between all of the different types during early development,” says Roska. “These sick starbursts hadn’t learned to distinguish between the left and right motion detectors, so the framework to compute sideways motion was missing.” 

How well these results translate into humans remains to be explored, but the group confirmed a similar link between FRMD7 and starburst cells in primates, suggesting that the visual systems may be comparable. While Roska’s next goal is to further explore FRMD7’s exact role, these results provide a valuable starting point for future nystagmus therapies, as well as the first evidence that a disease can be caused by faulty computation in the brain. 

Learn more about Roska’s research in this press release from the Friedrich Miescher Institute for Biomedical Research. 

Main image: This starburst cell (in green) looks healthy, but its faulty cellular contacts underlie the debilitating retinal disease nystagmus. Image by Botond Roska/FMI

Shareline

A cellular computing error wreaks havoc on vision.
Tweet Tweetpopo
Tags: 
Novartis Institutes for BioMedical Research, New Scientific Discoveries, Scientific Research, Genetic Disease

K.E.D. Coan

K.E.D. Coan

manages scientific and medical communications in Switzerland and made her debut as a science blogger in 2014. Although her days in the lab have ended for the moment, she finds writing a great way to keep close to the latest research.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Coronavirus
From Our Labs

A visual tour of scientific strategies for combating coronavirus

Wendi Yajnik, Global Head of Academic Partnerships and External Innovation for research
From Our Labs

Advancing medicine through collaboration

Special instrument controlled by a production associate
From Our Labs

Turning the power of nuclear technology into a medical force

You are here

  1. Home ›
  2. Stories ›
  3. From Our Labs

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.